Experience with Octreotide in patients with castration refractory prostate cancer

被引：0
|
作者：
Ganov, D. I. [1 ]
Varlamov, S. A. [1 ]
机构：
[1] Altai State Med Univ, Kussian Acad Med Sci, NN Blokhin Russian Canc Res Ctr, Altai Branch, Barnaul, Russia
来源：
ONKOUROLOGIYA | 2011年 / 7卷 / 04期
关键词：
castration refractory prostate cancer; sustained-release octreotide;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fifteen patients with castration refractory prostate cancer have been treated with sustained-release octreotide in combination with dexamethasone at the Altai Territory Oncology Dispensary since 2008. Control PSA test revealed that 9 (60 %) patients had positive changes; tumor process stabilization was noted in 4 (26.7 %) and only 2 (13.3 %) were found to have disease progression. Thus, more than 86 % of patients responded to combination treatment with sustained-release octreotide + dexamethasone. Octreotide treatment caused no serious specific adverse toxic reactions.
引用
收藏
页码：71 / 73
页数：3
相关论文
共 50 条
  • [11] Castration-refractory prostate cancer: New drugs in the pipeline
    Dirk Schrijvers
    Peter Van Erps
    Jim Cortvriend
    Advances in Therapy, 2010, 27 : 285 - 296
  • [12] New Therapeutic Agents for Castration-Refractory Prostate Cancer
    Patten, David Y.
    Sartor, Oliver
    CLINICAL GENITOURINARY CANCER, 2009, 7 (02) : E4 - E6
  • [13] Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
    Nityam Rathi
    Taylor Ryan McFarland
    Roberto Nussenzveig
    Neeraj Agarwal
    Umang Swami
    Drugs, 2021, 81 : 191 - 206
  • [14] Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
    Patel, Jesal C.
    Maughan, Benjamin L.
    Agarwal, ArchanaM.
    Batten, Julia A.
    Zhang, Tian Y.
    Agarwal, Neeraj
    PROSTATE CANCER, 2013, 2013
  • [15] SECONDARY HORMONAL MANIPULATIONS IN THE TREATMENT OF CASTRATION REFRACTORY PROSTATE CANCER
    Agarwal, Neeraj
    Vogelzang, Nicholas J.
    BJU INTERNATIONAL, 2011, 108 (02) : 227 - 228
  • [16] Perspectives on mTOR Inhibitors for Castration-Refractory Prostate Cancer
    Burgio, Salvatore L.
    Fabbri, Francesco
    Seymour, Ian J.
    Zoli, Wainer
    Amadori, Dino
    De Giorgi, Ugo
    CURRENT CANCER DRUG TARGETS, 2012, 12 (08) : 940 - 949
  • [17] Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
    Rathi, Nityam
    McFarland, Taylor Ryan
    Nussenzveig, Roberto
    Agarwal, Neeraj
    Swami, Umang
    DRUGS, 2021, 81 (02) : 191 - 206
  • [18] Castration Refractory Prostate Cancer: Cinderella Finally Comes to the Ball
    Chowdhury, Simon
    Harper, Peter
    Powles, Thomas
    ONKOLOGIE, 2010, 33 (12): : 655 - 656
  • [19] Castration-Refractory Prostate Cancer: New Drugs in the Pipeline
    Schrijvers, Dirk
    Van Erps, Peter
    Cortvriend, Jim
    ADVANCES IN THERAPY, 2010, 27 (05) : 285 - 296
  • [20] Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer
    Kalkner, KM
    Acosta, S
    Thorsson, O
    Frederiksen, H
    Nilsson, A
    Gustavsson, B
    Elingsbo, M
    Stridsberg, M
    Abrahamsson, PA
    PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (01) : 92 - 98
12345